STAT+: Drugmakers, biotech VCs show ‘reinvigorated’ interest in osteoporosis treatments
Investors are returning to bone-loss therapies as evidence for common supplements looks thin.
TL;DR
- Drugmakers and biotech venture investors are showing 'reinvigorated' interest in osteoporosis treatments, STAT reported.
- ScienceDaily reported that a major review found little benefit from the calcium and vitamin D that millions take for bone health.
- Neither item named specific deals or amounts in the collected headlines.
Drugmakers and biotech VCs are showing 'reinvigorated' interest in osteoporosis treatments, STAT reported. [1]
The evidence backdrop is shifting too: a major review found little benefit from the calcium and vitamin D supplements millions take for bone health, ScienceDaily reported. [2]
Why it matters
Renewed investor attention to a large, ageing-driven indication, alongside evidence that common supplements do little, points to room for prescription therapies. It is a pipeline and dealmaking theme to watch, not a signal about any individual treatment.
Editor's note
This item reports research and investment coverage only and is not guidance on supplement or drug use; deal details were not in the collected data.